Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir™ versus continued HAART: The trizal study

Alain Lafeuillade; Nathan Clumeck; Josep Mallolas; Hans Jaeger; Jean Michel Livrozet; Maria do Sameira Ferreira; Margaret Johnson; Arnaud Cheret; Zeina Antoun; J. Demonty; C. Bazin; M. Bentata; E. Bouvet; J. F. Delfraissy; P. Dellamonica; T. Saint Marc; L. De Saint Martin; P. De Truchis; G. Dien; H. Gallais; H. Gil; B. Hoen; C. Katlama; D. Lacoste; J. M. Lang; J. M. Livrozet; M. Beumont; P. Massip; W. Rozenbaum; D. Sereni; P. Yeni; S. Fenske; J. Rockstroh; B. Salzberger; D. Schuermann; S. Staszewski; F. Mulcahy; A. Lazzarin; F. Milazzo; M. Moroni; A. Cargnel; C. Santos; L. Flamholc; K. Koppel; P. Easterbrook; M. Fisher; B. Gazzard; G. Kinghorn; J. Weber; E. Wilkins

doi:10.1310/EJRF-JGGH-GRCD-MED8

Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir™ versus continued HAART: The trizal study

Alain Lafeuillade, Nathan Clumeck, Josep Mallolas, Hans Jaeger, Jean Michel Livrozet, Maria do Sameira Ferreira, Margaret Johnson, Arnaud Cheret, Zeina Antoun, J. Demonty, C. Bazin, M. Bentata, E. Bouvet, J. F. Delfraissy, P. Dellamonica, T. Saint Marc, L. De Saint Martin, P. De Truchis, G. Dien, H. GallaisH. Gil, B. Hoen, C. Katlama, D. Lacoste, J. M. Lang, J. M. Livrozet, M. Beumont, P. Massip, W. Rozenbaum, D. Sereni, P. Yeni, S. Fenske, J. Rockstroh, B. Salzberger, D. Schuermann, S. Staszewski, F. Mulcahy, A. Lazzarin, F. Milazzo, M. Moroni, A. Cargnel, C. Santos, L. Flamholc, K. Koppel, P. Easterbrook, M. Fisher, B. Gazzard, G. Kinghorn, J. Weber, E. Wilkins

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir™ (zidovudine, lamivudine, abacavir) after 48 weeks. Method: Patients treated with HAART >6 months with plasma HIV-1 RNA viral load (VL)

Original language	English
Pages (from-to)	37-43
Number of pages	7
Journal	HIV Clinical Trials
Volume	4
Issue number	1
DOIs	https://doi.org/10.1310/EJRF-JGGH-GRCD-MED8
Publication status	Published - Jan 2003

Keywords

Lipids
Lipodystrophy
Trizivir™

ASJC Scopus subject areas

Virology
Immunology

Access to Document

10.1310/EJRF-JGGH-GRCD-MED8

Cite this

Lafeuillade, A., Clumeck, N., Mallolas, J., Jaeger, H., Livrozet, J. M., do Sameira Ferreira, M., Johnson, M., Cheret, A., Antoun, Z., Demonty, J., Bazin, C., Bentata, M., Bouvet, E., Delfraissy, J. F., Dellamonica, P., Saint Marc, T., De Saint Martin, L., De Truchis, P., Dien, G., ... Wilkins, E. (2003). Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir™ versus continued HAART: The trizal study. HIV Clinical Trials, 4(1), 37-43. https://doi.org/10.1310/EJRF-JGGH-GRCD-MED8

Lafeuillade, A, Clumeck, N, Mallolas, J, Jaeger, H, Livrozet, JM, do Sameira Ferreira, M, Johnson, M, Cheret, A, Antoun, Z, Demonty, J, Bazin, C, Bentata, M, Bouvet, E, Delfraissy, JF, Dellamonica, P, Saint Marc, T, De Saint Martin, L, De Truchis, P, Dien, G, Gallais, H, Gil, H, Hoen, B, Katlama, C, Lacoste, D, Lang, JM, Livrozet, JM, Beumont, M, Massip, P, Rozenbaum, W, Sereni, D, Yeni, P, Fenske, S, Rockstroh, J, Salzberger, B, Schuermann, D, Staszewski, S, Mulcahy, F, Lazzarin, A, Milazzo, F, Moroni, M, Cargnel, A, Santos, C, Flamholc, L, Koppel, K, Easterbrook, P, Fisher, M, Gazzard, B, Kinghorn, G, Weber, J & Wilkins, E 2003, 'Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir™ versus continued HAART: The trizal study', HIV Clinical Trials, vol. 4, no. 1, pp. 37-43. https://doi.org/10.1310/EJRF-JGGH-GRCD-MED8

@article{79d0547283734e9ba35d4a5bee780f5a,

title = "Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir{\texttrademark} versus continued HAART: The trizal study",

abstract = "Purpose: To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir{\texttrademark} (zidovudine, lamivudine, abacavir) after 48 weeks. Method: Patients treated with HAART >6 months with plasma HIV-1 RNA viral load (VL) ",

keywords = "Lipids, Lipodystrophy, Trizivir{\texttrademark}",

author = "Alain Lafeuillade and Nathan Clumeck and Josep Mallolas and Hans Jaeger and Livrozet, {Jean Michel} and {do Sameira Ferreira}, Maria and Margaret Johnson and Arnaud Cheret and Zeina Antoun and J. Demonty and C. Bazin and M. Bentata and E. Bouvet and Delfraissy, {J. F.} and P. Dellamonica and {Saint Marc}, T. and {De Saint Martin}, L. and {De Truchis}, P. and G. Dien and H. Gallais and H. Gil and B. Hoen and C. Katlama and D. Lacoste and Lang, {J. M.} and Livrozet, {J. M.} and M. Beumont and P. Massip and W. Rozenbaum and D. Sereni and P. Yeni and S. Fenske and J. Rockstroh and B. Salzberger and D. Schuermann and S. Staszewski and F. Mulcahy and A. Lazzarin and F. Milazzo and M. Moroni and A. Cargnel and C. Santos and L. Flamholc and K. Koppel and P. Easterbrook and M. Fisher and B. Gazzard and G. Kinghorn and J. Weber and E. Wilkins",

year = "2003",

month = jan,

doi = "10.1310/EJRF-JGGH-GRCD-MED8",

language = "English",

volume = "4",

pages = "37--43",

journal = "HIV Clinical Trials",

issn = "1528-4336",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir™ versus continued HAART

T2 - The trizal study

AU - Lafeuillade, Alain

AU - Clumeck, Nathan

AU - Mallolas, Josep

AU - Jaeger, Hans

AU - Livrozet, Jean Michel

AU - do Sameira Ferreira, Maria

AU - Johnson, Margaret

AU - Cheret, Arnaud

AU - Antoun, Zeina

AU - Demonty, J.

AU - Bazin, C.

AU - Bentata, M.

AU - Bouvet, E.

AU - Delfraissy, J. F.

AU - Dellamonica, P.

AU - Saint Marc, T.

AU - De Saint Martin, L.

AU - De Truchis, P.

AU - Dien, G.

AU - Gallais, H.

AU - Gil, H.

AU - Hoen, B.

AU - Katlama, C.

AU - Lacoste, D.

AU - Lang, J. M.

AU - Livrozet, J. M.

AU - Beumont, M.

AU - Massip, P.

AU - Rozenbaum, W.

AU - Sereni, D.

AU - Yeni, P.

AU - Fenske, S.

AU - Rockstroh, J.

AU - Salzberger, B.

AU - Schuermann, D.

AU - Staszewski, S.

AU - Mulcahy, F.

AU - Lazzarin, A.

AU - Milazzo, F.

AU - Moroni, M.

AU - Cargnel, A.

AU - Santos, C.

AU - Flamholc, L.

AU - Koppel, K.

AU - Easterbrook, P.

AU - Fisher, M.

AU - Gazzard, B.

AU - Kinghorn, G.

AU - Weber, J.

AU - Wilkins, E.

PY - 2003/1

Y1 - 2003/1

N2 - Purpose: To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir™ (zidovudine, lamivudine, abacavir) after 48 weeks. Method: Patients treated with HAART >6 months with plasma HIV-1 RNA viral load (VL)

AB - Purpose: To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir™ (zidovudine, lamivudine, abacavir) after 48 weeks. Method: Patients treated with HAART >6 months with plasma HIV-1 RNA viral load (VL)

KW - Lipids

KW - Lipodystrophy

KW - Trizivir™

UR - http://www.scopus.com/inward/record.url?scp=0037226383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037226383&partnerID=8YFLogxK

U2 - 10.1310/EJRF-JGGH-GRCD-MED8

DO - 10.1310/EJRF-JGGH-GRCD-MED8

M3 - Article

C2 - 12577195

AN - SCOPUS:0037226383

SN - 1528-4336

VL - 4

SP - 37

EP - 43

JO - HIV Clinical Trials

JF - HIV Clinical Trials

IS - 1

ER -

Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir™ versus continued HAART: The trizal study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this